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Abstract
The lack of specific symptoms at early tumor stages, together with a high biological aggressiveness of the tumor contribute
to the high mortality rate for pancreatic cancer (PC), which has a five year survival rate of less than 5%. Improved screening
for earlier diagnosis, through the detection of diagnostic and prognostic biomarkers provides the best hope of increasing
the rate of curatively resectable carcinomas. Though many serum markers have been reported to be elevated in patients
with PC, so far, most of these markers have not been implemented into clinical routine due to low sensitivity or specificity.
In this study, we have identified genes that are significantly upregulated in PC, through a meta-analysis of large number of
microarray datasets. We demonstrate that the biological functions ascribed to these genes are clearly associated with PC
and metastasis, and that that these genes exhibit a strong link to pathways involved with inflammation and the immune
response. This investigation has yielded new targets for cancer genes, and potential biomarkers for pancreatic cancer. The
candidate list of cancer genes includes protein kinase genes, new members of gene families currently associated with PC, as
well as genes not previously linked to PC. In this study, we are also able to move towards developing a signature for
hypomethylated genes, which could be useful for early detection of PC. We also show that the significantly upregulated
800+ genes in our analysis can serve as an enriched pool for tissue and serum protein biomarkers in pancreatic cancer.
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Introduction
Pancreatic cancer (PC) is a highly lethal malignancy, and
patients with PC have a 5-year survival rate of less than 5% [1].
Thus, even though the incidence of breast cancer is estimated to
be 5 times greater than PC, the annual death rates are comparable
[2]. In nearly 95% of PC patients there is neither an associated
family history of PC nor of diseases known to be associated with an
increased risk of PC [3]. The lack of specific symptoms at early
tumor stages, together with a high biological aggressiveness of the
tumor and resistance to cytotoxic drugs all contribute to the high
mortality rate of PC.
This study has been motivated by two reasons. The First is to
contribute to the understanding of the fundamental disease
etiology of PC by identifying novel candidate cancer genes in
pancreatic cancer. The mutations found in a cancer cell genome
have generally accumulated over the lifetime of the cancer patient
and usually number between 1,000–10,000 [4]. For PC, exome
sequencing has revealed that the average number of mutations in
exons is about 60 [5]. Driver mutations [6] confer growth
advantage on the cells carrying them and are positively selected for
during the evolution of a cancer. It has been suggested that
common adult epithelial cancers require the activation of between
5–20 such driver genes [7,8]. The identification of driver
mutations and the cancer genes that they alter has been a central
aim of cancer research; so far, about 500 (2%) of the 22,000
protein-coding genes in the human genome are reported to show
recurrent mutations in cancer with strong evidence that these
contribute to cancer development [9] (http://www.sanger.ac.uk/
genetics/CGP/Census/). However, studies in mice have suggested
that more than 2,000 genes, when appropriately altered, may have
the potential to contribute to cancer development [10] indicating
that the search for cancer genes is far from over. A comprehensive
treatment protocol for pancreatic cancer would require first, the
identification of all the cancer genes, and next, the ability to
modulate the function of these genes through therapeutic
intervention. In recent years, the proteins altered by driver
mutations have become targets for successful anticancer drug
development [11–13].
The second impetus for this study comes from the paucity of
biomarkers in PC [14,15]. Improved screening for earlier
diagnosis, through the detection of diagnostic and prognostic
biomarkers, provides the best hope of increasing the rate of
curatively resectable carcinomas. For example, analysis of
sequence data has suggested that the time frame from the
initiation of the pancreatic tumor to the development of metastatic
subclones could be more than ten years [16]. Though many serum
markers has been reported to be elevated in patients with
pancreatic cancer, so far, most of these markers have not been
implemented into clinical routine due to low sensitivity or
specificity [14] with the exception of CA 19-9 [17].
Meta-analysis of microarray datasets consists of using statistical
techniques to combine results from several studies in order to
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increase statistical power and generalizability compared with any
single study [18]. This addresses, to some extent, the issues of
biological and technical variations, which can have a significant
effect on microarray measurements [19]. The previous meta-
analysis of microarray datasets on PC was conducted nearly a
decade ago by Grutzman and colleagues [20], and the analysis was
limited to a few thousand genes.
In this study, we examined the differential gene expression
patterns that are replicated across datasets, to create a ranked list
of genes overexpressed in PC. We focused our attention only on
genes that are overexpressed, since about 80% of cancer genes are
dominant acting [4] through either overexpression or constitutive
activation of gene product. In this study, we have detected
hundreds of genes that were significantly upregulated in pancreatic
cancer. The list of overexpressed genes include genes that have not
been previously associated with PC as well as new members of
gene families that have been associated with PC. We have also
identified tens of kinase-encoding genes overexpressed in pancre-
atic cancer, which are potential therapeutic targets for PC. In this
study, we are also able to move towards developing a signature for
hypomethylated genes, which could be useful for early detection of
PC. We also find that about a third of the putative protein serum
biomarkers thus far identified for PC are, in fact, significantly
overexpressed in our analysis, indicating that our results could
serve as a resource for further experimental studies, in the quest for
effective biomarkers for PC.
Materials and Methods
Pancreatic cancer microarray datasets
Nine pancreatic cancer datasets in the Oncomine database [21]
that contained a differential analysis of pancreatic cancer vs.
normal samples, were included this study (Table 1). Oncomine
[21] is the most comprehensive cancer-specific database, currently
containing 628 datasets investigating 35 tumor types (Oncomine
4.4 Research Edition). The advantage of using datasets from
Oncomine is that prior to inclusion in Oncomine, the microarray
datasets (obtained from public resources such as Stanford
Microarray Database and the NCBI Gene Expression Omnibus
or literature sources) are reviewed by a panel of experts to ensure
that they meet certain quality standards [22].
Initial screening of microarray datasets
Prior to combining microarray datasets from different sources, a
further quality check was performed on the datasets using the
program Venn Mapper [23]. Venn mapper can identify significant
similarities between heterologous microarray datasets, by compar-
ing the overlap of differentially expressed genes and calculating a
statistical significance using z-values. Briefly, a 2-fold cutoff is used
to determine the upregulated genes in a microarray dataset. A list
of upregulated genes is established for each microarray, and all
pair-wise (except self comparisons) combinations of lists are
compared for matching gene-identity (i.e. HUGO gene names).
The number of genes commonly upregulated, Robserved, in any two
experiments is determined, and a z-value is calculated to
determine whether this number is statistically significant. For








R = number of genes upregulated in both A and B
nB = Total number of genes upregulated in B
PA = Probability of a gene being upregulated in A
Microarrays were clustered based on z-value profiles, and any
outliers were identified, and omitted from further analysis. An
absolute z-value of .1.96 is equivalent to a p-value of ,0.05.
Obtaining ranked lists of upregulated genes
To identify differentially expressed genes across multiple
datasets, we employed a non-parametric ‘rank product’ method
implemented in the RankProd package [24,25]. RankProd is a
statistically rigorous but biologically intuitive algorithm, which has
been shown to be robust against noise in microarray data [26,27].
RankProd has been shown to have higher sensitivity and specificity
compared to other types of meta-analytic tools for microarrays
[28]. A list of upregulated genes are selected based on a
conservative estimation of the percentage of false positive
predictions (pfp), which is also known as the false discovery rate.
As recommended, a pfp value of ,0.15 [25] was used to set the
threshold for genes that are significantly upregulated.
Results and Discussion
Congruency between microarray datasets
The program Venn Mapper [23] was used to perform an initial
screening, to determine any broad inconsistencies that exist
between the microarray datasets. Analysis was carried out on
nine different datasets, and all-to-all pairwise z-values are given in
Table 2. Two outliers were identified by this method, namely,
Buchholz Pancreas (Pancreatic Ductal Adenocarcinoma) and
Buchholz Pancreas (Pancreatic Intraepithelial Neoplasia). The
low z-values associated with these datasets indicate a lack of
significant correlation between upregulated genes in these datasets,
when compared with other datasets. Hence, these two datasets
were omitted from further analyses. While we are uncertain about
the source of this incongruency, we note that the Buchholz
datasets were the only datasets obtained without the use of
standard (commercially available) platforms. Another dataset,
Logsdon Pancreas, was also omitted due to the low number of
genes in the dataset (5,338, compared to an average of 16,652
genes for the rest of the data (Table 1)).
Below, we organize our results and discussion into four discrete
sections that include identification of upregulated genes, functional
analysis of upregulated genes, identification of a genetic signature
for hypomethylation in PC, and identification of potential tissue,
serum and matrix metalloproteinase biomarkers in PC.
Identification of upregulated genes
RankProd [24] yields a list of genes ranked by percentage of
false positive prediction (pfp) value (see methods). Of the 5590
genes that were upregulated by at least two fold, 827 genes are
found to be significantly upregulated when using a pfp threshold of
,0.15 [25] (Table S1).
Table 3 provides a list of the top twenty-five ranked genes using
the RankProd program. As expected, most genes have well-
established associations with pancreatic and other cancers. Some
well-known examples include MUC4 [29], CEACAM5/6 [30],
S100P [31], CLDN18 [32], KRT19 (CK19) [33] and COLA1/2
[34]. There are, however, some notable exceptions such as
AHNAK2, CTHRC1, IGHG3 and EPPK1, which do not have a
known role in cancer. Hence, these genes can be potential new
leads for cancer genes, and are discussed next.
AHNAK2 is a significantly upregulated gene in PC (175-fold),
but has not been directly associated with any cancer, to our
knowledge. The mRNA is reported [35] to be alternatively spliced
to produce three isoforms, and the canonical sequence is inferred
to be targeted to the nucleus. The AHNAK family of scaffold PDZ
New Molecular Targets in Pancreatic Cancer
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proteins consists of two large proteins (600–700 kD), AHNAK
(desmoyokin) and AHNAK2 [36]. AHNAK has been associated
with several muscular diseases, including cardiomyopathy and
limb-girdle muscular dystrophy, and this effect is believed to be
mediated through its association with the b-subunit of cardiac
Ca(v) calcium channel [37]. AHNAK & AHNAK2 have also been
shown to be components of the costameric network, associated
with linking of the extracellular matrix to the cytoplasmic
microfilament system [38]. Experiments on metastatic human
tumor cell lines [39] have shown that knockdown of AHNAK
resulted in pseudopod retraction, inhibition of cell migration and
reversion of mesenchymal-epithelial transition (MET). It is likely
that AHNAK and AHNAK2 were both affected by these
knockdown experiments. Our results suggest that the family of
AHNAK proteins, particularly AHNAK2, merit experimental
scrutiny regarding their possible role in carcinogenesis, especially
in PC.
CTHRC1 (collagen triple helix containing 1) is a 30 kD
secreted protein that has the ability to inhibit collagen matrix
synthesis, and is highly expressed during skin wound healing.
Tissue repair and carcinogenesis are linked [40] and CTHRC1
has been associated with a variety of tumors including melanoma
[41], breast cancer [42], colorectal cancer [43] and most recently,
gastric cancer [44]. However, there has only been one report that
links CTHRC1 with PC, where higher expression of CTHRC1
was observed in a screen of solid tumor cell lines including PC
[41]. There is evidence that CTHRC1 expression is associated
with cancer tissue invasion and metastasis in breast cancer [42]
and gastric cancer [44]. Given the high level of upregulation of
CTHRC1 (.1,000-fold) that was observed in this study, we
hypothesize CTHRC1 to be an excellent candidate for experi-
mental evaluation as a potential biomarker for PC.
IGHG3 (Immunoglobulin heavy constant c-3) is a secreted
antigen binding protein not previously implicated in pancreatic
cancer. Our analysis (see next section) indicates that PC is
associated with dysfunction of the immune system. IGHG3 is also
a component of the top network associated with the cohort of 827
overexpressed genes, which is shown in Figure 1.
Table 1. Pancreatic Cancer Microarray Datasets Included in the Study.
Dataset Name* Cancer Type Genes** Platform Dataset Summary*
Badea Pancreas Pancreatic Ductal Adenocarcinoma 19,574 Human Genome U133
Plus 2.0 Array
Paired pancreatic ductal
adenocarcinoma (n = 39) and normal
pancreas (n = 39) samples from 36
patients were analyzed; three patients
were analyzed in duplicate.
Buchholz Pancreas Pancreatic Ductal Adenocarcinoma 15,725 Human Genome Oligo-Set-
Version 2.0 (Operon, Germany)
Eight (8) pancreatic ductal
adenocarcinoma and 6 normal
pancreatic duct samples were analyzed.
Buchholz Pancreas Pancreatic Intraepithelial Neoplasia 15,736 Human Genome Oligo-Set-
Version 2.0 (Operon, Germany)
Twenty-four (24) pancreatic
intraepithelial neoplasia and 6 normal
pancreatic duct samples were analyzed.
Grutzmann Pancreas Pancreatic Ductal Adenocarcinoma 17,782 Human Genome U133A Array,
Human Genome U133B Array
Fourteen (14) microdissected pancreatic
ductal adenocarcinoma and 11 normal
pancreatic duct samples were analyzed.
Sample data includes type, age, grade,
TNM stage, and sex.
Ishikawa Pancreas Pancreatic Ductal Adenocarcinoma 17,782 Human Genome U133A Array,
Human Genome U133B Array
Twenty-four (24) pancreatic ductal
adenocarcinoma and 25 normal
pancreatic duct samples were analyzed.
Sample data includes type, age, atypical
cell proportion, clinical stage,
cytological grade, and sex.
Iacobuzio-Donahue
Pancreas 2
Pancreatic Ductal Adenocarcinoma 14,361 Non standard Fourteen (14) pancreatic carcinoma cell
lines, 17 primary pancreatic ductal
adenocarcinoma samples of various
histologies, and 5 normal pancreas
samples were analyzed.
Logsdon Pancreas Pancreatic Adenocarcinoma 5,338 HumanGeneFL Array Ten microdissected adenocarcinoma, 7
pancreatic cancer cell lines, 5
pancreatitis, and 5 normal pancreas
samples were analyzed. Sample data
includes type and cell line name.
Pei Pancreas Pancreatic Ductal Adenocarcinoma 19,574 Human Genome U133 Plus
2.0 Array
Thirty-six (36) pancreatic carcinoma and
16 paired normal samples, for a total of
52 samples, were analyzed. Sample data
includes age and sex.
Segara Pancreas Pancreatic carcinoma 12,684 Human Genome U133A Array Eleven (11) pancreatic adenocarcinoma
samples and six (6) adjacent normal
pancreas samples from 12 patients were
analyzed.
*As identified by the Oncomine database.
**Number of genes probed.
doi:10.1371/journal.pone.0093046.t001
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Table 2. Pairwise z-values* Indicating Congruency between Upregulated Genes.
Name Badea1 Buch_DAC2 Buch_Intra3 Grutzmann4 Iacobuzio5 Ishikawa6 Logsdon7 Pei8
Buch_DAC 0.6
Buch_Intra 0.2 17.6
Grutzmann 9.7 20.2 20.6
Iacobuzio 9.7 20.1 20.6 5.2
Ishikawa 4.4 20.6 20.6 7.8 2.1
Logsdon 14.9 0.1 20.9 8.7 9.5 1.3
Pei 20.8 20.6 21.5 12.4 12.3 4.2 13.9
Segera9 17.5 0.7 0.4 7.2 8.2 6.1 11.5 12.7
*A z-value of .1.96 indicates a p-value of ,0.05.
1Badea Pancreas (Pancreatic Ductal Adenocarcinoma).
2Buchholz Pancreas (Pancreatic Ductal Adenocarcinoma).
3Buchholz Pancreas (Pancreatic Intraepithelial Neoplasia).
4Grutzmann Pancreas (Pancreatic Ductal Adenocarcinoma).
5Iacobuzio-Donahue (Pancreatic Adenocarcinoma).
6Ishikawa Pancreas (Pancreatic Ductal Adenocarcinoma).
7Logsdon Pancreas (Pancreatic Adenocarcinoma).
8Pei Pancreas (Pancreatic Ductal Adenocarcinoma).
9Segera Pancreas (Pancreatic Carcinoma).
doi:10.1371/journal.pone.0093046.t002
Table 3. A List of the 25 Most Highly Ranked Upregulated Genes in Pancreatic Cancer.
Gene* Gene Function
AHNAK2 Unknown; a component of the costameric network
CDH3 A calcium-dependent cell adhesion molecule.
CEACAM5 Cell surface glycoprotein that plays a role in cell adhesion and in intracellular signaling; binds with another CEACAM to function.
CEACAM6 A cell adhesion molecule; mediates cell adhesion by binding with another CEACAM (21, 25, and 26 are most common).
CLDN18 Plays a major role in tight junction-specific obliteration of the intercellular space, through calcium-independent cell-adhesion activity
COL11A1 This gene encodes one of the two alpha chains of type XI collagen, a minor fibrillar collagen.
COL1A1 Type 1 collagen is a fibril forming collagen found in most connective tissue; alpha chain one.
COL1A2 Type 1 collagen is a fibril forming collagen found in most connective tissue; alpha chain two.
CTHRC1 May play a role in the cellular response to arterial injury through involvement in vascular remodeling. (secreted)
CTSE A gastric aspartyl protease that functions as a disulfide-linked homodimer.
EPPK1 Unknown. May play a role in supporting the intermediate filaments
FN1 Fibronectin is involved in cell adhesion and migration processes including embryogenesis, wound healing, blood coagulation, host
defense, and metastasis. (secreted)
GPRC5A Unknown. May be involved with the interaction between retanoic acid and the G protein sigaling pathway.
IGHG3 Unknown; Immunoglobulin heavy chain gamma 3
KRT19 Involved in the organization of myofibers. Together with KRT8, helps to link the contractile apparatus to dystrophin at the costameres of
striated muscle.
MMP11 Weakly degrades structural proteins of the ECM.
MUC4 Mucins are glycoprotein that play a role in the protection of epithelial cells. Implicated in renewal and differentiation.
OLFM4 An antiapoptotic factor that promotes tumor growth and is an extracellular matrix glycoprotein that facilitates cell adhesion.
POSTN Induces cell attachment and spreading and plays a role in cell adhesion.
S100P S100 proteins are involved in the regulation of a number of cellular processes such as cell cycle progression and differentiation.
SERPINB5 Unknown. Exhibits no serine protease inhibitory activity functions as a tumor suppressor of mammary tumors
SLC6A14 A member of the solute carrier family; transports both neutral and cationic amino acids
VCAN This protein is involved in cell adhesion, proliferation, migration and angiogenesis and plays a central role in tissue morphogenesis and
maintenance
THBS2 A disulfide-linked homotrimeric glycoprotein that mediates cell-to-cell and cell-to-matrix interactions
COL3A1 Pro-alpha1 chain of type III collagen, a fibrillar collagen that is found in extensible connective tissue.
*Gene names are given according to the HUGO Gene Nomenclature Committee (HGNC).
doi:10.1371/journal.pone.0093046.t003
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Epiplakin belongs to the plakin family of cytolinker proteins that
are associated with the junctional complexes and the cytoskeleton.
Epiplakin is rather an unusual plakin in that it consists solely of
plakin repeats organized into 13 plakin repeat domains (PRD’s)
and does not contain a plakin domain characteristic of other
plakins. There is evidence to suggest that Epiplakin associates with
keratin networks during wound healing [45].
Functional analysis of the upregulated genes
We identified important functions, networks, and pathways
relevant to the 827 significantly upregulated genes using IPA
(www.ingenuity.com). A comprehensive analysis of the 827
upregulated genes is shown in Table S1.
The most significant biological functions associated with the 827
upregulated genes are cellular movement, cellular growth and
proliferation, cell death and survival, cellular development and
cell-to-cell signaling and interaction (Figure 2, Table S2).
Dysregulation of these functions are associated with cancer and
metastasis, reiterating the importance of this geneset to PC. A
pathway analysis provided insights into some of the molecular
mechanisms important in PC. The five most significant pathways
associated with the 827 upregulated genes included integrin
signaling (p-value = 1.72610213), also observed by Grutzmann et
al. [20], granulocyte adhesion and diapedesis (p-val-
ue = 4.08610211), agranulocyte adhesion and diapedesis (p-
value = 9.43610210), leukocyte extravasation signaling (p-val-
ue = 1.6261029), and virus entry via endocytic pathways (p-
Figure 1. Top scoring network associated with the upregulated genes in PC. TGFB1 forms a hub node in the network. IGHG3 (highlighted in
blue color) is one of the top twenty-five genes that is potentially important for pancreatic cancer.
doi:10.1371/journal.pone.0093046.g001
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value = 1.7161028) (Figure 3, Table S3). These results indicated
that PC is significantly associated with inflammation and immune
mechanisms. In fact, it has been shown that cancer immunosup-
pression often favors tumor progression and metastasis by
constituting an immunosuppressive network in which several
tumor-derived soluble factors such as interleukin-10, transforming
growth factor beta (TGFB) and vascular endothelial growth factor
play central roles [46]. In the top network identified, TGFB1 is the
hub gene (Figure 1). TGFB1 encodes a member of the TGFB
family of cytokines, which are multifunctional peptides that
regulate proliferation, differentiation, adhesion, migration, and
other functions in many cell types. This gene has been shown to be
frequently upregulated in tumor cells, and is an important target
for cancer therapy [47–51].
The second most significant network associated with the
upregulated genes is involved in cell cycle, cellular movement,
and cancer (Figure 4). In this network, NF-kB complex acts as a
major hub, which functions as a regulator of genes that control cell
proliferation and cell survival. Incorrect regulation of NF-kB has
been linked to cancer, inflammatory and autoimmune diseases
[52,53]. This network again suggests that PC could be closely
correlated with immunological disorder [54,55]. Upregulated NF-
kB turns on the expression of genes that keep the cell proliferating,
and protect the cell from conditions that would otherwise cause it
to die via apoptosis. In fact, it has been shown that NF-kB is
constitutively active in various types of human tumors [56–60]. In
addition, there are two interesting regulatory modules identified in
this network. The first module is made up of two E2F family genes
(E2F7, E2F8), ECT2 and RACGAP1. These genes form
autoregulatory loops, and regulate each other. Notably, the three
genes E2F7, E2F8 and ECT2 constitutively regulate RACGAP1,
which binds to Rho GTPases (Figure 4), suggesting that this
module functions in the regulation of cytokinesis in a cell cycle-
dependent manner. Another module involves the glutathione
peroxidase (GPX) family genes that encode an enzyme family with
peroxidase activity, whose main biological role is to protect the
organism from oxidative damage. Upregulation of GPX family
genes may be associated PC and other cancers [61–64], suggesting
an important link between oxidatively-induced DNA damage and
cancer development.
Identification of the upregulated kinase-encoding genes
Furthermore, we extracted the genes encoding protein kinases
from the 827 upregulated genes. Table 4 presents the 26 kinase-
Figure 2. Important biological functions and diseases associated with genes upregulated in PC.
doi:10.1371/journal.pone.0093046.g002
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encoding genes. It has been known that many kinase-encoding
genes are upregulated in cancer, and development of anticancer
drugs that inhibit overexpression of protein kinases has been an
active area of research. In fact, effective drugs have already been
developed to target some of the protein kinases. For example,
CDK1 encodes a member of the Ser/Thr protein kinase family,
which is a catalytic subunit of the highly conserved protein kinase
complex known as M-phase promoting factor. The protein plays a
key role in G1/S and G2/M phase transitions of eukaryotic cell
cycle, and the phosphorylation and dephosphorylation of this
protein play important regulatory roles in cell cycle control [65].
Some CDK1 kinase inhibitors have been developed for clinical or
experimental purposes - AZD 5438, (R)-CR8, (R)-DRF053
dihydrochloride, Kenpaullone, NU 2058, and Ro 3306 (Tocris
Bioscience, www.tocris.com), and ZK 304709 and Terameprocol
[66].
LCK is a tyrosine-protein kinase that is found inside lympho-
cytes of the immune system, and involved in immune signaling
pathways. Dasatinib, a small-molecule protein tyrosine kinase
inhibitor and anticancer drug, can inhibit LCK activity in T-cell
activation and proliferation [67,68]. MET is a proto-oncogene
that encodes the hepatocyte growth factor receptor protein [69],
which possesses tyrosine-protein kinase activity. Abnormal upre-
gulation of MET in cancer often correlates with poor prognosis by
triggering tumor growth, angiogenesis that supply the tumor with
nutrients, and metastasis. It has been revealed that the MET
pathway is one of the most frequently dysregulated pathways in
human cancer [70]. A substantial number of MET inhibitors have
been studied in clinical trails like AMG-458 (Amgen), PF-
04217903 (Pfizer), MK-2461(Merck), ARQ197 (ArQule) etc. [71].
TTK encodes a dual specificity protein kinase with the ability to
phosphorylate tyrosine, serine and threonine. TTK kinase is
associated with cell proliferation and is essential for the proper
attachment of chromosomes to the mitotic spindle. Inhibition of
TTK kinase has been shown to correlate with cell death caused by
chromosomal missegregations [72]. Several TTK kinase inhibitors
have been reported in the literature – Reversine [73], NMS-P715
[74], and MPS1-IN-1 [75].
For some other tyrosine-protein kinases such as LYN, Dasatinib
is an effective inhibitor [76]. Of the 26 kinase-encoding genes we
identified, some genes have been identified as very promising
anticancer targets. For example, BUB1 encoding the mitotic
checkpoint serine/threonine-protein kinase is critical in the
establishment of the mitotic spindle checkpoint and chromosome
congression. It has been shown that disturbed mitotic checkpoints
are a common feature of many human cancers [77]. However,
BUB1 expression levels depend on the localization of tumors and
their severity [78]. Downregulation of BUB1 resulted in more
sarcomas, lymphomas and lung tumors, whereas upregulation of
BUB1 caused sarcomas and tumors in the liver [78]. Our result
shows that PC is related to the upregulation of BUB1 and we
speculate that development of BUB1 inhibitors could provide a
new approach to tackling PC.
To sum up, some of the 26 significantly upregulated protein
kinase genes in PC could be viable new therapeutic targets for PC.
In fact, for the tyrosine-protein kinase genes such as LCK, MET
and LYN, which have been found to be frequently overexpressed
in human cancer including PC [79], effective tyrosine-protein
kinase inhibitors such as Dasatinib, Imatinib, Gefitinib, Erlotinib,
and Sunitinib have been developed for anticancer chemotherapy
[80].
Towards a genetic signature for hypomethylation in
pancreatic cancer
Aberrant hypermethylation of promoter CpG islands is tightly
associated with gene silencing, whereas hypomethylation can lead
to the upregulation of genes. A recent review [81], discusses genes
that have been found to be hypomethylated in PC. With reference
to this gene set, we do find a strong correlation between
hypomethylation and upregulation; specifically, seven of nine
genes mentioned in this review (SERPINB5, CLDN4, SFN,
S100P, S100A4, MSLN, and PSCA) are significantly upregulated,
with SERPINB5, SFN, S100P, and PSCA being among the 100
most upregulated genes in our analysis (Table S1).
A comprehensive study on aberrant methylation in PC has been
performed by Tan et al. [82], who profiled 1505 CpG sites across
807 genes. Initial investigations yielded a list of 63 genes with CpG
site hypomethylation and increased mRNA expression. Somewhat
unexpectedly, the authors also found a similar number of genes
with CpG site hypomethylation and decreased mRNA expression.
Upon further experimentation, 35 of the 63 genes were identified
by the authors as candidate genes that are regulated by
hypomethylation in PC. We find that eight of the 35 candidate
genes (ID1, MMP7, MST1R, NBL1, PHLDA2, PLAT, PLAUR
Figure 3. The five most significant pathways associated with genes upregulated in PC are related to inflammation and immune
response.
doi:10.1371/journal.pone.0093046.g003
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and SFN), and a further 8 (IL8, SPP1, CLDN4, MMP1,
ARHGDIB, NQO1, ITGB4, SERPINB5, and TFF1) from the
original list of 63 genes are also significantly upregulated in our
study.
To summarize, twenty-two genes (MUC4, SERPINB5,
CLDN4, SFN, TFF1, S100P, S100A4, MMP1, MMP7, MSLN,
PSCA, ID1, MST1R, NBL1, PHLDA2, PLAT, PLAUR, IL8,
SPP1, ARHGDIB, NQO1, and ITGB4) are significantly upregu-
lated in our analysis, and there is experimental evidence [81,82] to
suggest that this upregulation is due to hypomethylation. Thus,
these genes will contribute towards a growing list of candidates
including MUC4 [83] that describe a putative genetic signature
for hypomethylation in pancreatic cancer (Table 5). Such a genetic
signature could prove to be useful in the early detection of PC, in a
manner analogous to the clinical use of aberrant methylation of
CCND2 [84] in PC. Since there is an emerging consensus that
‘epigenetic chaos’ promoted changes in gene expression and,
ultimately, leads to cancer [85], it is quite likely that many of the
genes found to be significantly upregulated (Table S1) are
hypomethylated in PC. Of the 22 genes, IPA analysis reveals that
11 genes have a known association with PC (Table 5).
Potential biomarkers among upregulated genes
Tumor tissue protein biomarkers. An observation often
reported in literature is the discrepancy between the level of
expression of a protein and that of its transcript for a given type of
cell [86]. Nonetheless, we find about 70% of thirty two tumor
tissue protein biomarkers identified in two recent reviews [87,88]
were found to be upregulated .2-fold in our analysis. Among
those significantly upregulated (pfp,0.15) were a cluster of genes
associated with the actin microfilament, lGAlS1 (galectin-1),
ACTN4 (actinin-4), PLS1 (plastin-1), TPM2 (tropomyosin b),
CFL1 (cofilin-1), ENO1 (a-enolase), and MSN (moesin). Most of
these proteins are known actin-binding proteins that can modulate
Figure 4. The second most significant network associated with the upregulated genes in PC. A major hub node NF-kB complex, and two
new regulatory modules are highlighted in blue color. One module is made up of two E2F family genes (E2F7, E2F8), ECT2 and RACGAP1; and another
module is made up of several GPX family genes.
doi:10.1371/journal.pone.0093046.g004
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the actin microfilament, or modulate its environment with the
plasma membrane.
Other suggested tumor tissue protein biomarkers [87,88]
significantly upregulated in our analysis include SFN, AGR2,
LGALS1, LGALS3, THBS2, & TGFB1, and four members of the
S100 family, S100A6, S100A10, S100A11, and S100A2 [89]. We
find three additional members of the S100 family, S100A4,
S100A16 and S100P were also significantly upregulated (Table
S1). The S100 family of low molecular weight calcium binding
proteins have strong associations with cancer [90], and several of
them have been used as markers in melanoma and other cancers.
It should be noted that S100P is one of the most upregulated genes
in our analysis (.6106). It has recently been proposed that S100P
be used as a protein biomarker for intraductal papillary mucinous
neoplasms (IPMN) of the pancreas [91], and for pancreatic
adenocarcinoma [92].
Serum protein biomarkers. Early diagnosis of pancreatic
cancer is essential in order to improve the poor prognosis
associated with PC. Serum biomarkers offer a very attractive
and non-invasive solution, and are thus highly sought after [14].
However, there is a paucity of serum biomarkers for PC [15], with
the carbohydrate biomarker CA 19-9 being the most widely used.
Since serum protein biomarkers such as CA-125 may be cleaved
and released in PC [93] a correlation between serum biomarkers
and mRNA expression is not necessarily expected (though in the
case of CA-125, there is evidence that it is overexpressed as well
[93]). Nevertheless, we sought to investigate whether any of the
proposed serum protein biomarkers in the recent literature [3]
were upregulated in pancreatic cancer at the level of mRNA.
Somewhat to our surprise, we found that about one-third of the
corresponding genes, C3, B2M, C1QB, CD9, TIMP1, PGK1,
SERPINA1, APOE, AGR2, APOC1 & SPP1, were significantly
upregulated in our analysis. These results indicate our corhort of
827 significantly upregulated genes also represent an enriched pool
of candidate serum protein biomarkers. The commercial avail-
ability of many human antibodies raises the intriguing possibility of
performing a systematic screen of serum, to detect for protein
products of significantly upregulated genes in our analysis. While
individual biomarkers may suffer from issues of sensitivity and
specificity [14], the promise is that with a large number of
biomarkers, distinctive signatures are likely to emerge, that
correlate with diagnosis and prognosis.
Matrix metalloproteinase biomarkers. Matrix metallo-
proteases represent the most prominent family of proteinases
associated with tumorigenesis [94]. In our analysis, we found that
seven matrix metalloproteases (MMPs) and six proteases from a
related family ‘‘a disintegrin and metalloprotease’’ (ADAMs) to be
significantly upregulated (Table 6). Three of these (MMP9,
ADAM9 and ADAM10) were also found to be upregulated by
Grutzman et al. [20].
Matrix metalloproteases are a family of zinc-dependent
proteases that have the capacity to degrade virtually every
component of the extracellular matrix (ECM). Tumor cells
overexpress these proteases in order to degrade the basement
membrane and invade the surrounding tissue. This activity is also
required for the intravasation and extravasation events in
metastasis. MMP substrates also include non-ECM molecules,
ranging from growth factor precursors and cell surface adhesion
molecules to angiogenic inhibitor precursors [95]. MMPs have
also been implicated in the epithelial to mesenchymal transition
(EMT) [96]. While MMPs have well-recognized roles in the late
stage of tumor progression, invasion, and metastasis, emerging
evidence suggests that the role of MMPs in tumorigenesis is more
complex [97].
One of the more promising and exciting applications of MMPs
in human cancers is as potential cancer biomarkers, both
diagnostic and prognostic. MMP-2, MMP-7 and MMP-9 are
among the most well studied matrix metalloproteases in PC [98].
MMP-9 expression has been linked to worse prognosis, and it also
significantly correlated with tumor expression and distant metas-
tasis [99]. Active MMP-2 levels are upregulated in the pancreatic
juice of patients with cancer (100%) as compared with patients
with chronic pancreatitis (2%) or normal controls (0%) [100]
Similarly, plasma as well as tumor tissues from patients with
pancreatic ductal adenocarcinoma have significantly elevated
MMP-7 levels, which may predict shortened survival of patients
[101].
As expected, MMP-2, MMP-7 and MMP-9 are all significantly
upregulated in our study. However, another matrix matallopro-
tease, MMP-11, is the most highly upregulated MMP, with an
average .10,000 fold overexpression in PC. MMP-11 induction
in adipose tissue has been linked to cancer progression [102] and
MMP-11 has been associated with tumor progression in pulmo-
nary cancer [103], head and neck carcinoma [104] and breast
carcinoma [105]. MMP-11 is known to cleave IGF binding
proteins, which regulate the bioavailability of insulin-like growth
Table 4. Twenty-six Kinase-encoding Genes Upregulated in
Pancreatic Cancer.
Gene* Description
ACVR1 Activin A receptor, type I
BUB1 Budding uninhibited by benzimidazoles 1 homolog (yeast)
BUB1B Budding uninhibited by benzimidazoles 1 homolog beta (yeast)
CDK1 Cell division cycle 2, G1 to S and G2 to M
DYRK2 Dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2
EPHA4 EPH receptor A4
IRAK3 Interleukin-1 receptor-associated kinase 3
LCK lymphocyte-specific protein tyrosine kinase
LYN V-yes-1 Yamaguchi sarcoma viral related oncogene homolog
MAP4K4 Mitogen-activated protein kinase 4
MELK Maternal embryonic leucine zipper kinase
MET Met proto-oncogene (hepatocyte growth factor receptor)
MST1R Macrophage stimulating 1 receptor (c-met-related tyrosine kinase)
MST4 Serine/threonine protein kinase MST4
NEK2 NIMA (never in mitosis gene a)-related kinase 2
NUAK1 NUAK family, SNF1-like kinase, 1
PBK PDZ binding kinase
PRKCI Protein kinase C, iota
PTK6 PTK6 protein tyrosine kinase 6
STK17B Serine/threonine kinase 17b
STK24 Serine/threonine kinase 24 (STE20 homolog, yeast)
STYK1 Serine/threonine/tyrosine kinase 1
TNIK TRAF2 and NCK interacting kinase
TRIB2 Tribbles homolog 2 (Drosophila)
TTK TTK protein kinase
UHMK1 U2AF homology motif (UHM) kinase 1
*Gene names are given according to the HUGO Gene Nomenclature Committee
(HGNC).
doi:10.1371/journal.pone.0093046.t004
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factors (IGFs). We also found two other MMPs known to cleave
IGF binding proteins, MMP-1 and MMP-2, as well as ADAM12,
to be significantly upregulated. While the failure of MMP
inhibitors in clinical trials has been disappointing [106], our
results indicate that MMPs continue to be attractive therapeutic
targets for PC.
Tumor tissue heterogeneity. Most cancers are believed to
originate through of a process of Darwinian evolution occurring
among the cells within the microenvironments provided by the
tissues of a multicellular organism. It has become increasingly clear
that this process can give rise to tumor tissue heterogeneity [107],
with distinct populations of cancer cells predominating in
pancreatic and other tumors [16] [108]. For example, this also
provides a mechanism for the development of drug resistance,
whereby a minor drug resistant subclone in the original tumor
becomes dominant after treatment [109]. In this context it is
possible that for the datasets in our study, the number of cancer
genomes sampled was higher than the number of patient samples.
The task of identifying and validating diagnostic and prognostic
biomarkers is likely to be complicated by the existence of tumor
heterogeneity.
Sample heterogeneity. Most microarray datasets specifically
cited the patient samples as being from either pancreatic
adenocarcinoma (PAC) or pancreatic ductal adenocarcinoma
(PDAC) (Table 1). These samples could still contain contaminants
from the desmoplasia, particularly in studies where microdissec-
tion was not used (Table 1), contributing to sample heterogeneity.
Table 5. A Putative Genetic Signature of Hypomethylated Genes in Pancreatic Cancer.
Gene pfp value Log (2) value Reference*
MUC4
$ 0.000 6.28 Zhu et al., 2011 [83]
SERPINB5 0.000 8.34 Sato et al., 2003 [110]; Fitzgerald et al., 2003 [111]; Ohike et al., 2003 [112]
CLDN4 0.103 2.67 Sato et al., 2003 [110], Tan et al., 2009 [82] (Gastric sarcoma Kwon et al., 2011 [113])
SFN 0.000 7.91 Sato et al., 2003 [110], Tan et al., 2009 [82] (Lung adenocarcinoma Shiba-Ishii et al., 2012
[114])
TFF1
$ 0.001 7.27 Tan et al., 2009 [82] (Prostrate cancer Vestergaard et al., 2010 [115])
S100P
$ 0.000 24.25 Sato et al., 2003 [110]
S100A4 0.004 3.12 Rosty et al., 2002 [116]
MMP1 0.003 4.63 Tan et al., 2009 [82]
MMP7
$ 0.011 4.07 Tan et al., 2009 [82]
MSLN
$ 0.026 4.80 Sato et al., 2003 [110] (Mesothelioma Nelson et al., 2011 [117])
PSCA
$ 0.001 7.78 Sato et al., 2003 [110]
ID1
$ 0.151 2.06 Tan et al., 2009 [82]
MST1R 0.025 3.40 Tan et al., 2009 [82]
NBL1 0.035 2.82 Tan et al., 2009 [82]
PHLDA2 0.000 5.22 Tan et al., 2009 [82] (Osteosarcoma Li et al., 2008 [118])
PLAT
$ 0.014 3.34 Tan et al., 2009 [82]
PLAUR
$ 0.014 3.18 Tan et al., 2009 [82]
IL8 0.007 4.21 Tan et al., 2009 [82] (Colorectal adenocarcinoma Dimberg et al., 2012 [119])
SPP1
$ 0.044 2.14 Tan et al., 2009 [82] (Liver fibrosis Komatsu et al., 2012 [120])
ARHGDIB 0.021 2.40 Tan et al., 2009 [82]
NQO1 0.000 6.19 Tan et al., 2009 [82]
ITGB4
$ 0.014 3.06 Tan et al., 2009 [82]
*References for hypomethylation in other cancers are given in parenthesis.
$
IPA analysis indicates a known association with PC.
doi:10.1371/journal.pone.0093046.t005
Table 6. Matrix Metalloproteinases Upregulated in Pancreatic
Cancer.
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If significant contamination of tumor samples from immune
components of the desmoplasia has occurred, it can have an
impact on the association we found by IPA analysis between PC
and inflammation/immune mechanisms. It should be noted that
there is also support for an association between PC and
inflammation from the literature (which we have cited previously).
A second source of sample heterogeneity is the type of PC. One
study (Pei Pancreas) did not specifically mention PAC or PDAC
under the dataset summary, and thus could conceivably contain
samples from other types of PC, although PDAC accounts for over
90% of the cases of PC.
The broad concordance observed between the microarray
datasets (see Congruency between microarray datasets) suggests
that issues related to sample heterogeneity (as well as other sources
of variation between the microarray datasets) were not a major
complicating factor in this meta-analysis. This observation also
strengthens the case for investigating differentially regulated genes
as putative biomarkers for PC.
Conclusions
Meta-analysis of multiple microarray datasets can yield more
reliable and comprehensive results than using a single dataset,
because the former has increased statistical power and generaliz-
ability. In the present study, we performed a meta-analysis of nine
PC datasets and identified 827 genes that are significantly
upregulated in pancreatic cancer. The two most important
biological networks associated with these genes have TGFB1
and NF-kB as major hubs. A pathway analysis indicates that PC is
significantly associated with inflammation and immune mecha-
nism.
Among the list of candidate cancer genes uncovered by this
study are four highly expressed genes not previously associated
with PC, and twenty-six kinase genes. Kinases have been attractive
targets in combating cancer, and in fact, effective therapeutics
have already been developed for several kinases in our list.
Importantly, this study also revealed potential biomarkers for
pancreatic cancer. Such biomarkers are in urgent need, given the
poor prognosis after (the normally late) diagnosis of PC. Towards
this end, we have also developed a putative genetic signature for
hypomethylated genes in PC. The identification of candidate
cancer genes and putative biomarkers for pancreatic cancer
provide new opportunities for early diagnosis and treatment of PC.
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